Recombinant human growth hormone (HuGH) and human prolactin (HuPRL), but not GH of bovine or porcine origin, prime human neutrophils for enhanced superoxide anion (O°) secretion. Since HuGH, but not GH of other species, effectively binds to the HuPRL receptor (HuPRL-R), we used a group of HuGH variants created by site-directed mutagenesis to identify the receptor on human neutrophils responsible for HuGH priming. A monoclonal antibody (MAb) directed against the HuPRL-R completely abrogated O2 secretion by neutrophils
Introduction
After binding to cellular membrane receptors, growth hormone (GH)' promotes growth and differentiation of a variety of cell types (1-3), including hemopoietic tissue (4) (5) (6) . Human GH (HuGH), but not GH ofother species (7, 8) , has a pleiotropic receptor-binding capacity (1) . Indeed, many of the biological effects of HuGH are shared with prolactin (PRL) because HuGH can bind and activate both somatogenic and lactogenic receptors. The lactogenic receptor-mediated effects, such as enhanced thymulin production by rat thymic epithelial cells, can occur via binding of HuGH to the rat PRL receptor (PRL-R) (9) . In contrast, human PRL (HuPRL) binds only to the lactogenic receptor and does not bind to the somatogenic receptor (7, 8) .
The mechanism by which HuGH exerts its pleiotropic effects has not been well defined beyond the level of interaction with a surface receptor (1) . Among those homologous receptors to which HuGH can bind, only two have been cloned, the HuGH-R (10, 11) and the HuPRL-R (12, 13) , although there are likely to be others such as the receptor for placental lactogen (14) . HuGH residues which are critical for binding to either the HuGH-R or HuPRL-R have been identified by analyzing segment-substituted and single residue-substituted HuGH variants, produced by site-directed mutagenesis techniques, with a competitive binding assay using the extracellular binding proteins derived from the receptors (15) (16) (17) (18) . Additionally, the variants were used to demonstrate that zinc mediates binding of HuGH to the HuPRL-R (15) . Three amino acids ofthe HuGH molecule, residues 18 (His), 21 (His), and 174 (Glu), coordinate with residue 188 (His) of the HuPRL-R to form the four zinc ligands. These zinc ligands appear to be critical for determining the binding preference of HuGH because mutants that alter these positions (15) bind preferentially to somatogenic rather than to lactogenic receptors ( 18) .
GH is now recognized to regulate both the differentiation and activation of lymphoid and myeloid cells (5) . We have demonstrated that GH increases the resistance ofrats to Salmonella typhimurium by increasing the ability of macrophages to kill S. typhimurium (19) and to secrete tumor necrosis factor-a (20) . GH also augments the capacity ofboth macrophages (21, 22) and neutrophils (23) to secrete°2 in response to triggering stimuli such as opsonized-zymosan, formylmethionyl-leucylphenylalanine (FMLP) and phorbol myristate acetate (PMA). In the present report, we used the model of human neutrophils that were primed with HuGH, HuPRL, or HuGH variants, in conjunction with monoclonal antibodies (MAbs) against either HuGH-R or HuPRL-R, to determine which receptor is responsible for augmenting the secretion of O2 after stimulation of human neutrophils with PMA. Based on four distinct lines of evidence, we demonstrate that the HuPRL-R can account for the HuGH-mediated priming of human neutrophils for an enhanced respiratory burst.
binding affinity for the HuGH-or HuPRL-binding protein (BP) as described (17, 18) . The binding affinities of HuGH variants that were designed to discriminate between the HuGH-R and HuPRL-R are described in Table I. Neutrophil isolation. Heparinized human venous blood was collected from healthy, 20-35-yr-old volunteers. Whole blood was gently mixed with an equal volume of 3% dextran (T500, Pharmacia LKB Biotechnology, Inc., Piscataway, NJ). The dextran solution was prepared in HBSS (without Ca", Mg", or phenol red; Gibco Laboratories, Grand Island, NY). The suspension was allowed to settle for 30 min at room temperature. The leukocyte-rich plasma was collected from the upper portion of the suspension and carefully layered onto Ficollpaque (density 1.077, Pharmacia LKB Biotechnology, Inc.). The gradient was centrifuged at 500 g, 20'C for 35 min. The supernatant, including platelets and the mononuclear leukocyte-rich fraction, was removed and the erythrocyte and neutrophil-rich pellet was resuspended with 0.2% saline and was then immediately brought up to isotonicity with an equal volume of 1.6% saline. Neutrophils were washed once by centrifugation and finally resuspended with HBSS. Whole blood yielded 3-5 X 106 cells/ml, consisting of > 95% neutrophils as determined by Wright Giemsa differential staining and with a viability > 99% assessed by trypan blue exclusion.
Porcine neutrophils were isolated from venous blood as described (23) . Bovine neutrophils were isolated according to the protocol of Carlson and Kaneko (24) . Briefly, heparinized bovine blood was diluted 1: 1 with HBSS and centrifuged at 500 g, 20°C for 35 min. After removal of plasma and buffy coat, the pellet was resuspended with 0.2% saline to lyse erythrocytes and was immediately reconstituted to isotonicity with an equal volume of 1.6% saline. After the second lysis, neutrophils were washed and resuspended in HBSS.
Priming of neutrophils. Neutrophils were maintained in a serumfree suspension in HBSS during the course of treatment (23 Co.) . Reduction ofcytochrome c was measured continuously at 550 nm (with asband width of 0.5 nm) after addition of PMA. The amount of°2 production in a period of 10 min was calculated based on the extinction coefficient of cytochrome c of 21 mM-'cm-'. Results are shown as the mean (n = 3)±SEM ofPMA-triggered°2 production by 2 X 106 neutrophils in 10 min.
Nb2 cell proliferation assay. The rat lymphoma cell line, Nb2 (27) , was maintained in suspension cultures in Fischer's medium (Gibco Laboratories) supplemented with horse serum (10%, Pel-Freez Biologicals, Rogers, AR), fetal calf serum (FCS, 10%, Hyclone Labs., Inc., Logan, UT), 2-mercaptoethanol (10-' M, Sigma Chemical Co.), penicillin (50 U/ml), and streptomycin (50 jig/ml) in an atmosphere of 5% CO2 at 37°C. Approximately 24 h before the Nb2 cells were used in the proliferation assay, they were transferred to Fischer's medium supplemented as above but containing only 0.5% FCS and 5% horse serum. At the end ofthis preincubation, cells were washed once by centrifugation (10 min at 300 g) and resuspended in Fischer's medium supplemented only with 2-mercaptoethanol and antibiotics. Cellswere distrib- Statistical analysis. Duncan's multiple-range test was used to determine the differences between treatments and all data were analyzed using a general linear model (28) .
Results
HuGH and HuPRL, but not PoGH or BoGH, prime human neutrophilsfor O2 secretion. We recently reported that human and porcine neutrophils can be primed with recombinant (17) .
HuGH or PoGH, respectively, for enhanced 0°secretion in response to PMA stimulation (23) . This GH-induced priming was dose-dependent and the minimum dose required to detect significant enhancement of O2 secretion was -100 ng/ml. Subsequently, we tested the priming capacity of another human pituitary hormone, recombinant PRL, on human neutrophil 0°secretion. A similar priming capacity of HuPRL was observed, but only half as much HuPRL (50 ng/ml) was required to significantly prime human neutrophils for enhanced O2 secretion (data not shown). At a higher dose (250 ng/ml), both HuPRL and HuGH potently enhanced 0°production by human neutrophils (P < 0.01; Fig. 1 ). However, GH of other species (porcine and bovine) that does not bind to the PRL-R (13) but bind, albeit poorly, to the HuGH-R (-1,000-fold less than HuGH; 29), failed to prime human neutrophils even at 10,000 ng/ml. Both rPoGH and rBoGH showed dose-dependent activity in augmenting the secretion of O2 by PMA-triggered neutrophils from pigs and cows, respectively (Fig. 2) . These results are in agreement with our previous findings (23) and further indicate that priming of neutrophils for°2 secretion by GH is conserved in a variety ofspecies and that both the GH-R and PRL-R may be involved in this activation.
HuGH-mediated priming can be abrogated by a MAb against the HuPRL-R. Both HuGH-and HuPRL-mediated priming (250 ng/ml each) of human neutrophils for 02 secretion were virtually abolished by a MAb (9D1 1, 500 ng/ml) against the HuPRL-R (P < 0.01, Fig. 3 (23) and demonstrated in Fig. 3 , bottom. Another murine MAb that had an identical isotype, anti-HuIGF-I-R (aIR3, 500 ng/ml), abrogated the HuIGF-I-mediated enhancement of O2 secretion by neutrophils (P < 0.01) but not the priming mediated by HuGH or HuPRL. However, the antiHuPRL-R MAb, at the same concentration used in Fig. 3 , top, could not block HuIGF-I-mediated priming of neutrophils, indicating that these MAbs are specific for their respective ligands. These results strongly suggest that the HuPRL-R is responsible for most of the priming induced by HuGH.
Priming of human neutrophils for enhanced O°secretion with HuGH variants. A group of variants that were created by site-directed mutagenesis were designed to discriminate between binding to either the HuGH-BP or HuPRL-BP (Table I; 17, 18) . We tested these variants for their functional capacity to prime human neutrophils for O2 secretion in comparison with wild-type HuGH (Fig. 4) . Recombinant HuGH wild type, at 250 and 2,500 ng/ml, primed neutrophils significantly (P < 0.01). HuGH variant, K172A/F176A, which has decreased binding affinity for both HuGH-BP and HuPRL-BP, did not prime these cells even at 2,500 ng/ml. This result indicates that a ligand-receptor interaction whose epitope is similar to the GH or PRL receptor site is required for GH to augment the secretion of O2 by human neutrophils. The HuGH variant K168A/E174A, which has a 34,000-fold greater preference for binding the HuGH-BP than the HuPRL-BP, did not prime neutrophils for significantly enhanced 0°secretion. In contrast, the variant E56D/R64M, which has a 30-fold reduction in affinity for the HuGH-BP and a marginally lower affinity for the HuPRL-BP (an 14-fold increase in preference for the HuPRL-BP), primed neutrophils for enhanced°2 secretion as effectively as the wild-type HuGH. These data strongly support the possibility that HuGH-mediated priming ofhuman neutrophils for 0°secretion is mostly mediated by binding to the HuPRL-R rather than to the HuGH-R.
Growth Hormone, Neutrophils, and Prolactin Receptors 453 Analysis ofthe biological activity ofHuGH variants by the Nb2 lymphoma proliferation assay. One possible explanation for the lack of priming activity exhibited by variants Kl 72A/ F176A and K168A/E 174A might be the loss oftheir biological activity owing to disturbances in secondary and tertiary structures of these molecules. To address this issue, we tested the biological activity of these HuGH variants, along with both positive (FCS, HuGH, and HuPRL) and negative (HuIGF-I) controls using a highly sensitive assay which detects PRL-Rdependent stimulation of Nb2 cell proliferation at a level of PRL as low as 10 pg/ml (27) . As shown in Fig. 5 TdR. FCS was used as a positive control, which showed a dose-dependent stimulation of Nb2 cell proliferation (P < 0.05 at 1% and P < 0.01 at 10%). HuIGF-I was used as a negative control to show the specificity of this assay. Significant proliferation of Nb2 cells (P < 0.01) was detected at concentrations of 0.1 ng/ml and greater of HuPRL, HuGH wild type, or variant E56D/R64M, while 1 and 10 ng/ml were required for significant (P < 0. (15) . However, binding of HuGH to the HuGH-R and binding ofHuPRL to the HuPRL-R are independent of zinc. Therefore, we tested the effect of exogenous zinc (from 25 to 100 uM) on the priming of human neutrophils induced by either HuGH or HuPRL. As shown in Fig. 6 , HuGH at 25 ng/ml was unable to induce priming in the absence of additional zinc. Exogenous zinc (from 25 to 100 ,gM) by itself had no effect on control neutrophils. However, exogenous zinc significantly boosted HuGH (25 ng/ml)-mediated enhancement in O2 secretion to a level comparable to that of human neutrophils treated with a 10-fold higher concentration (250 ng/ml). Priming neutrophils with HuGH at 250 ng/ml was independent of exogenous zinc. Zinc did not alter the secretion of O2 by human neutrophils that were primed with HuPRL and triggered with PMA (data not shown). Since the level of zinc plays a critical role in mediating the binding of HuGH to the HuPRL-R, but not of HuGH to the HuGH-R or of HuPRL to the HuPRL-R (15), these data reinforce the previous conclusion that HuGH binds to the HuPRL-R to augment the secretion of O2 by human neutrophils.
Discussion
In this report, four lines of evidence suggest that the relevant receptor by which HuGH augments the secretion of O2 by human neutrophils is primarily the HuPRL-R, not the HuGH-R. O2 by human neutrophils. However, recombinant GH molecules derived from two nonprimate species that do not bind to the HuPRL-R are unable to prime human neutrophils even though they are capable of enhancing the secretion of O2 by species-specific neutrophils. (b) A MAb directed against either the HuGH-R or HuPRL-R was used. Only the antibody against the HuPRL-R totally blocked the priming of human neutrophils incubated with either HuPRL or HuGH. (c) Alanine-and homologue-scanning mutagenesis were used to generate a set of predesigned HuGH variants that differentially bind to either the HuGH-R or HuPRL-R. The variant that did not bind either receptor was unable to augment the secretion of O2 by human neutrophils, which indicates that the priming of human neutrophils by HuGH or HuPRL requires a functional ligand-receptor interaction. More importantly, the variant that bound preferentially to the HuPRL-R was able to enhance O2 secretion by human neutrophils whereas the response induced by the HuGH-R specific analog was much reduced. (d) Exogenous zinc was able to augment the respiratory burst of human neutrophils when HuGH, but not HuPRL, was used. Since zinc is required for binding of HuGH to the HuPRL-R, but not for HuGH binding to the HuGH-R or for HuPRL binding to the HuPRL-R, these data also argue that the HuPRL-R is the relevant receptor for priming human neutrophils for O2 secretion.
The conclusion that the HuPRL-R is primarily responsible for HuGH-mediated priming of human neutrophils for O2 secretion is similar to the finding that HuGH stimulates rat thymulin production by binding to the PRL-R rather than to the GH-R on rat thymic epithelial cells (9) . Unlike HuGH, rat GH does not bind to the PRL-R and fails to exert a PRL-R-mediated stimulatory effect on thymulin production. However, the ability of GH to prime neutrophils for O2 secretion may be conserved in a variety of species (23 and Fig. 2 ). For example, neither porcine nor bovine GH bind to the PRL-R but they prime porcine and bovine neutrophils, respectively, for O2 secretion, suggesting that the GH-R mediates the priming ofboth porcine and bovine neutrophils by their own GH. Although HuGH binds to the HuGH-R, data in our report suggest a unique feature of the human neutrophil is that the PRL-R is primarily involved in modulating this HuGH-mediated functional activation of neutrophils. Accordingly, our data imply that the GH-R is ofreduced importance on human neutrophils or that HuGH is preferentially directed to the HuPRL-R due to the inevitable presence of zinc. There are no reports on the expression of either GH-R or PRL-R on neutrophils, although receptors for both hormones have been detected on human lymphocytes (29, 31, 32). Our preliminary results suggest the presence of both mRNAs for the GH-R and for the PRL-R in human neutrophils, as assessed by the polymerase chain reaction, RNA-RNA-hybridization techniques, and the presence of the PRL-R, but not the GH-R, in neutrophil membrane extracts as determined by Western blot analysis (data not shown). The expression of a functional HuGH-R on human neutrophils may therefore be subject to post-translational regulation. It is also important that both PRL- (33) (34) (35) (36) and GH-(37-39) like molecules are synthesized by lymphoid cells and that PRL augments a number ofimmune responses such as contact sensitivity reactions (4, 40) , synthesis of interferon-y (41) and expression of receptors for interleukin 2 (42).
Chimeric molecules or variants of HuGH that are generated by site-directed mutagenesis have proven to be powerful tools for studying ligand-receptor interactions. Using this ap-proach, our results not only couple ligand-receptor binding with direct functional activation of human neutrophils, but they also suggest the exclusiveness of the PRL-R in mediating the effect of HuGH in this system. Another report demonstrated that a GH variant generated by a similar technique acts as a GH antagonist which suppresses growth oftransgenic mice by blocking the GH-R without stimulating release ofits physiological mediator, IGF-I (43) . Therefore, in addition to data on the receptor-binding affinity ofthese variants, measurement of functional activities using biological assays can provide important clues about understanding the relevant events that occur after ligand-receptor interaction.
Like HuGH, human placental lactogen (PL) binds to the PRL-R (44) There are considerable data which demonstrate that zinc plays a critical role in several physiological systems and that zinc affects many functions of both the peripheral nerves (46, 47) and cells of the immune system, including neutrophils, and it is now apparent that zinc deficiency suppresses several components of the immune system (48-52). The present report is the first to show that by mediating the binding of HuGH to the PRL-R, zinc augments the secretion ofO-by human neutrophils incubated with HuGH. Since both the GH-R and PRL-R are homologous to the receptors of the cytokine receptor gene superfamily (53) (54) (55) , zinc may also be involved in mediating other cytokine actions by ligand-receptor binding.
